Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Management of Bartholin’s cyst and abscess, Gynaecology (066)
Announcements and latest updates

Welcome to the Right Decision Service (RDS) newsletter for August 2024.

  1. Contingency planning for RDS outages

Following the recent RDS outages, Tactuum and the RDS team have been reviewing the learning from these incidents. We are committed to doing all we can to ensure a positive outcome by strengthening the RDS to make it fully robust and clinically resilient for the future.

We would like to invite you to a webinar on 26th September 3-4 pm on national and local contingency planning for future RDS outages.  Tactuum and the RDS team will speak about our business continuity plans and the national contingency arrangements we are putting in place. This will also be a space to share local contingency plans, ideas and existing good practice. We would also like to gather your views on who we should send communications to in the event of future outages.

I have sent a meeting request for this date to all editors – please accept or decline to indicate attendance, and please forward on to relevant contacts. You can also contact Olivia.graham@nhs.scot directly to register your interest in participating.

 

2.National  IV fluid prescribing  calculator

This UK CA marked calculator is now live at https://righdecisions.scot.nhs.uk/ivfluids  . It has been developed by a multiprofessional steering group of leads in IV fluids management, as part of the wider Modernising Patient Pathways Programme within the Centre for Sustainable Delivery.  It aims to address a known cause of clinical error in hospital settings, and we hope it will be especially useful to the new junior doctors who started in August.

Please do spread the word about this new calculator and get in touch with any questions.

 

  1. New toolkits

The following toolkits are now live;

  1. Updated guidance on current and future Medical Device Regulations

We have updated and simplified this guidance within our standard operating procedures. We have clarified the guidance on how to determine whether an RDS tool is a medical device, and have provided an interactive powerpoint slideset to steer you through the process.

 

  1. Guide to six stages of RDS toolkit development

We have developed a guide to support editors and toolkit leads through the process of scoping, designing, delivering, quality assuring and implementing a new RDS toolkit.  We hope this will help in project planning and in building shared understanding of responsibilities throughout the full development process.  The guide emphasises that the project does not end with launch of the new toolkit. Implementation, communication and evaluation are ongoing activities throughout the lifetime of the toolkit.

 

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:
  • Thursday 5 September 1-2 pm
  • Wednesday 24 September 4-5 pm
  • Friday 27 September 12-1 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

7 Evaluation projects

Dr Stephen Biggart from NHS Lothian has kindly shared with us the results of a recent survey of use of the Edinburgh Royal Infirmary of Edinburgh Anaesthesia toolkit. This shows that the majority of consultants are using it weekly or monthly, mainly to access clinical protocols, with a secondary purpose being education and training purposes. They tend to find information by navigating by specialty rather than keyword searching, and had some useful recommendations for future development, such as access to quick reference guidance.

We’d really appreciate you sharing any other local evaluations of RDS in this way – it all helps to build the evidence base for impact.

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

 

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

Management of Bartholin’s cyst and abscess, Gynaecology (066)

Warning

Objectives

To provide guidance on the management of those presenting with and Bartholin’s cyst or abscess

Audience

All healthcare professionals involved in the care of women with a Bartholin’s cysts or abscess

Please report any inaccuracies or issues with this guideline using our online form

The Bartholin’s gland is a mucus secreting gland located bilaterally at the base of the labia minora, at the level of the hymen. When the duct becomes blocked, a cyst may form and the gland may be palpable. If the cyst becomes infected, an abscess may form which can cause severe pain. The life-time risk is approximately 3%. 

Clinical Features

Patients will present with a painful unilateral swelling in the vagina. 

On examination, there will be a tender, erythematous swelling at 4 or 8 o’clock on the lateral vaginal wall. Tracking of the abscess along the vaginal wall may cause cellulitis. 

Differential diagnosis

  • Inclusion cyst
  • Gartner duct cyst
  • Haematoma
  • Sebaceous cyst
  • Lipoma
  • Hidradenitis suppurativa
  • Endometriosis

Investigations

A charcoal swab should be obtained from the cyst/abscess and sent for culture and sensitivity. It is estimated that >70% of cysts are culture sterile, and only 33% of abscess cultures are sterile.

Bartholin’s duct abscesses may be polymicrobial: E. coli (single most common pathogen), followed by infections including Staphylococcus aureus, Group B streptococci and Enterococci species. Neisseria gonorrohoea may be identified.

Additional appropriate swabs should be obtained for chlamydia and gonorrohoea if there is risk of a sexually transmitted infection. 

Biopsy

A biopsy may be indicated in women over 40 years old as there is an increased risk of adenocarcinoma of the Bartholin’s gland. 

Management

This will depend on the severity and the duration of the patient’s symptoms in addition to patient preference.   

Recurrence rates are not consistently reported.  However, one RCT (WoMan trial) summarised that Marsupialisation and Word catheter recurrence at 12 months are similar (10-12%).   Where incision and drainage or needle aspiration is performed, recurrence is thought to be higher, and therefore should be avoided if possible.  The aim should being to create a new mucocutaneous junction between the wall of the cyst and the skin of the labia to allow continued drainage.

Conservative management, no signs of infection

Hot baths several times per day and simple analgesia.  In the absence of cellulitis, antibiotics are not indicated.

Conservative management, no surgical intervention with suggestion of mild infection with presence of cellulitis or offensive discharge.  A review of any previous swabs should be undertaken.

Where antibiotic treatment is required, suggested regimes are

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

Or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Word Balloon Catheter

This treatment should be used first line in the surgical management of Bartholin’s cysts or abscesses. This is a very well tolerated procedure and has good operative success. 

The Word catheter kits contain the 3cm long catheter, a syringe for inflation and the scalpel. A local anaesthetic, such as 1% lidocaine, may be used to infiltrate the skin prior to the initial incision being made. Via a 5mm stab incision into the mucosal surface of the labia minora, just exterior to the hymen ring, within the introitus in the region of the normal duct opening. 

A charcoal swab should be obtained from the discharging fluid. 

The catheter is inserted and inflated with a maximum of 3ml of saline, as per the manufacturer’s guidelines. If the balloon is overfilled this may cause extra discomfort so the balloon should be deflated by extracting some saline. If the incision is made too large the catheter may fall out so an anchor suture may be required to hold it in place.

The patient can go home with the catheter in situ and usually this stays in for 4 weeks to encourage formation of an epithelialised fistula and prevent refilling of the abscess. A patient information leaflet should be given with a contact number for the gynaecology emergency service.

After 4 weeks, the catheter is deflated and removed. If the catheter falls out at home during this time it may be left out provided the patient’s symptoms are resolving. 

Where there are no signs of infection, antibiotic cover is not required.

Consideration should be made to cover with broad spectrum antibiotics if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis.  A review of any previous swab results should be undertaken.

Where antibiotic treatment is required suggest

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Marsupialisation 

Where there is a recurrent abscess or if patient would prefer to avoid Word Catheter insertion, marsupialisation under a general anaesthetic should be performed. The purpose of this is to create a fistula and prevent further abscess formation. Packing is not routinely required. 

In theatre, a single dose of intravenous antibiotic cover should be given.

1.2g of co-amoxiclav, IV

or

900mg of clindamycin, IV

Consideration should be made to continue cover with broad spectrum antibiotics, particularly if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis. 

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Follow up

This is not routinely required after marsupialisation of the cyst or abscess.

If patients have already been commenced on oral antibiotics, they may wish to complete the course. However, they do not routinely need to start treatment after the initial dose in theatre, if there are no signs suggestive of infection.

Simple vulval hygiene advice should include avoiding bubble baths, lotions or talcum powder. Sexual intercourse should be avoided until there is no pain or discharge. 

Editorial Information

Last reviewed: 14/06/2023

Next review date: 16/05/2026

Author(s): Joy SimpsonDr Joy Simpson, Consultant O&G PRM.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 066

Related resources
References

Balloon catheter insertion for Bartholin's cyst or abscess | Guidance and guidelines | NICE

Inserting an inflatable balloon to treat a bartholin’s cyst or abscess Interventional Procedure guidance 323. December 2009. National Institute for Health and Clinical Excellence (NICE)

Wechter Wu, Marzano and Haefner. Management of bartholin duct cyst and abscesses. A systematic review. Obstetrical and Gynaecolocal Survey; 64(6) 2009. 

BMJ Best Practice, Bartholin's cyst - Symptoms, diagnosis and treatment, August 2022.

Omole F et al. Bartholin Duct Cyst and Gland Abscess: Office ManagementAm Fam Physician. 2019;99(12):760-766

Kroese AJ et al. Word catheter and marsupialisation in women with a cyst or abscess of the Bartholin gland (WoMan-trial): a randomised clinical trial. BJOG. 2017 Jan;124(2):243-249.